Ironwood Pharmaceuticals (IRWD) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Meeting called to order by the Chair, conducted virtually via live audio webcast.
Board members, executive officers, and external auditor introduced; notice of meeting confirmed.
Quorum presumed present; voting procedures and shareholder list access explained.
Shareholder proposals
Three proposals presented: election of nine directors, advisory vote on executive compensation, and ratification of the independent auditor.
No additional nominations or proposals were received in advance.
Overview of voting outcomes
All nine director nominees elected by plurality of votes cast.
Advisory vote on executive compensation approved by majority.
Ratification of Ernst & Young LLP as independent auditor for 2024 approved by majority.
Final voting results to be filed with the SEC via Form 8-K.
Latest events from Ironwood Pharmaceuticals
- LINZESS U.S. net sales jumped 97% year-over-year, fueling strong Q1 profits and outlook.IRWD
Q1 20267 May 2026 - Board recommends voting for all proposals, including equity plan amendment and auditor ratification.IRWD
Proxy filing28 Apr 2026 - Key votes include director elections, executive pay, equity plan expansion, and auditor ratification.IRWD
Proxy filing28 Apr 2026 - 2026 guidance targets $1.125B–$1.175B LINZESS U.S. net sales and >$300M adjusted EBITDA.IRWD
Q4 20257 Apr 2026 - LINZESS growth funds apraglutide's development, with pivotal trial and NDA submission targeted for 2029.IRWD
The Citizens Life Sciences Conference 202611 Mar 2026 - LINZESS demand rose 11% but pricing pressure cut revenue; apraglutide advanced toward NDA filing.IRWD
Q2 20242 Feb 2026 - Apraglutide's strong data and once-weekly dosing position it for broad US market success.IRWD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Apraglutide is set to launch in 2026, targeting $1B peak sales and replacing Linzess revenue.IRWD
2024 Wells Fargo Healthcare Conference22 Jan 2026 - LINZESS demand grew 13% year-over-year, but Q3 revenue and profits declined.IRWD
Q3 202416 Jan 2026